医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Harris Healthcare Solutions Achieves Critical Milestone in Secure Exchange of Health Information

2013年10月07日 PM09:25
このエントリーをはてなブックマークに追加


 

MELBOURNE, Fla. & WASHINGTON

Harris Corporation (NYSE:HRS), an international communications and information technology company, has successfully deployed its Service Oriented Architecture (SOA) Suite solution enabling the U.S. Department of Veterans Affairs (VA) and the Department of Defense (DoD) to securely exchange health information. The SOA Suite is now “production capable” which means it is certified and available to register clinical or business process applications and manage communications.

The deployment is a critical milestone in a multi-year, $80 million healthcare integration contract awarded to Harris in March 2012. The SOA Suite enables the seamless communication between disparate healthcare applications at the VA and DoD, allowing information sharing and clinical collaboration never before possible between the agencies.

Harris’ SOA Suite helps the VA and DoD exchange health information to manage care and enhance outcomes for millions of active duty and retired military personnel and their families. It also fosters a new era in technical innovation for the agencies, allowing them to rapidly integrate and test new clinical applications before making them available to the healthcare community.

“Harris supports the goal of providing a seamless transition for active service members from the DoD’s healthcare system to the VA’s healthcare system upon their transition from active duty. Millions of service members and their families can begin to experience continuity of care for the first time ever,” stated Dr. Vishal Agrawal, president, Harris Healthcare Solutions. “Harris’ SOA Suite solution provides a solid foundation for business process interoperability between the VA and DoD healthcare systems.”

A nationally recognized leader in clinical connectivity, collaboration, and intelligence solutions, Harris offers a full range of interoperability solutions, including IT infrastructure and management, clinical workflow and analytics, health information exchange, and imaging. Harris solutions improve health-care quality, safety, efficiency, cost and outcomes by ensuring that the right information travels, with security and privacy, to the right person, at the right time, on the right device, at the point of care.

About Harris Corporation

Harris is an international communications and information technology company serving government and commercial markets in more than 125 countries. Headquartered in Melbourne, Florida, the company has approximately $5 billion in annual revenue and about 14,000 employees — including 6,000 engineers and scientists. Harris is dedicated to developing best-in-class assured communications® products, systems and services. Additional information about Harris Corporation is available at harris.com.

Forward-Looking Statements

This press release contains forward-looking statements that reflect management’s current expectations, assumptions and estimates of future performance and economic conditions. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company cautions investors that any forward-looking statements are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements. Statements about the expected value of the program to Harris are forward-looking and involve risks and uncertainties. Harris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT

Harris Healthcare Solutions
Eileen Cassidy Rivera, 703-610-4216
eileen.rivera@harris.com
or
Harris
Corporation
Jim Burke, 321-727-9131
jim.burke@harris.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表